280 related articles for article (PubMed ID: 26002404)
1. Potentiators for cystic fibrosis - targeting the underlying molecular defect.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Paediatr Respir Rev; 2015 Jun; 16(3):162-4. PubMed ID: 26002404
[No Abstract] [Full Text] [Related]
2. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
3. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
4. Therapeutic benefit of ivacaftor in late cystic fibrosis caused by homozygous IVS8-5T CFTR polymorphism.
Magne F; Durupt S; Nove-Josserand R; Bey-Omar F; Laoust L; Cottin V; Durieu I; Reynaud Q
J Cyst Fibros; 2017 Jan; 16(1):89-90. PubMed ID: 27810230
[No Abstract] [Full Text] [Related]
5. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
6. Ivacaftor and Airway Inflammation in Preschool Children with Cystic Fibrosis.
McNally P; Butler D; Karpievitch YV; Linnane B; Ranganathan S; Stick SM; Hall GL; Schultz A
Am J Respir Crit Care Med; 2021 Sep; 204(5):605-608. PubMed ID: 34077699
[No Abstract] [Full Text] [Related]
7. Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del.
Mainz JG; Arnold C; Hentschel J; Tabori H
Arch Bronconeumol (Engl Ed); 2018 Apr; 54(4):232-234. PubMed ID: 29103672
[No Abstract] [Full Text] [Related]
8. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study.
Davies JC; Cunningham S; Harris WT; Lapey A; Regelmann WE; Sawicki GS; Southern KW; Robertson S; Green Y; Cooke J; Rosenfeld M;
Lancet Respir Med; 2016 Feb; 4(2):107-15. PubMed ID: 26803277
[TBL] [Abstract][Full Text] [Related]
9. A safety evaluation of ivacaftor for the treatment of cystic fibrosis.
McColley SA
Expert Opin Drug Saf; 2016 May; 15(5):709-15. PubMed ID: 26968005
[TBL] [Abstract][Full Text] [Related]
10. Positive clinical outcomes following ivacaftor treatment in a cystic fibrosis patient with the genotype 3272-26A > G/Q493X.
Pallin M; Daley CP
J Cyst Fibros; 2020 Jan; 19(1):e3-e4. PubMed ID: 31771899
[No Abstract] [Full Text] [Related]
11. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
12. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Elborn JS; Davies J
Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
[No Abstract] [Full Text] [Related]
13. Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Antoniu SA
Expert Opin Investig Drugs; 2011 Mar; 20(3):423-5. PubMed ID: 21303308
[TBL] [Abstract][Full Text] [Related]
14. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
Ramsey BW; Welsh MJ
Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
[No Abstract] [Full Text] [Related]
15. The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.
Dryden C; Wilkinson J; Young D; Brooker RJ;
Arch Dis Child; 2018 Jan; 103(1):68-70. PubMed ID: 27288428
[TBL] [Abstract][Full Text] [Related]
16. Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor.
Chassagnon G; Hubert D; Fajac I; Burgel PR; Revel MP;
Eur Respir J; 2016 Jul; 48(1):249-52. PubMed ID: 27230445
[No Abstract] [Full Text] [Related]
17. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
Talamo Guevara M; McColley SA
Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
[TBL] [Abstract][Full Text] [Related]
18. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
19. Targeting the basic defect in cystic fibrosis.
Welsh MJ
N Engl J Med; 2010 Nov; 363(21):2056-7. PubMed ID: 21083391
[No Abstract] [Full Text] [Related]
20. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis.
Habib AR; Kajbafzadeh M; Desai S; Yang CL; Skolnik K; Quon BS
Sci Rep; 2019 May; 9(1):7234. PubMed ID: 31076617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
